Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-115 drug-drug interaction study with pioglitazone, losartan, and midazolam in solid tumors
jRCT2031210372Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pamufetinib in Nonhematologic neoplasms and osteosarcoma (OS), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetic parameters of pioglitazone, Pharmacokinetic parameters of losartan and 1 more. Started Dec 2021; status: completed.
02
Drugs
pamufetinib
03
Conditions
Nonhematologic neoplasmsosteosarcoma (OS)
Beyond the preview
Go deeper on jRCT2031210372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210372.